TNXP: NDA Filed for TNX-102 SL in Fibromyalgia

358 Views03 Dec 2024 16:00
Issuer-paid
On October 16, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that it submitted the New Drug Application (NDA) for TNX-102 SL for the...
What is covered in the Full Insight:
  • Introduction
  • NDA Submission Details
  • Clinical Trial Results Overview
  • Market Potential
  • Financial Outlook
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Zacks Small Cap Research
Research Coverage on Small and Micro-Cap Companies
Zacks Small Cap Research
Equity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • TNXP: NDA Filed for TNX-102 SL in Fibromyalgia
    03 Dec 2024
x